Azitra, Inc. Announces New U.S. Patent Protecting ATR-12 Program
A patent has been granted for ATR-12, a genetically modified strain of S. epidermidis that produces a portion of human LEKTI protein. ATR-12 is under Phase 1b testing for treating Netherton syndrome. The location of this development is BRANFORD, Conn., as of May 6, 2026. Azitra, Inc. (NYSE...) is leading this innovative venture.
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments